摘要
随着基因蛋白组学和分子生物检测技术的进步,晚期肺癌的诊疗已经从传统的放化疗迈向精准的靶向治疗。针对表皮生长因子受体(EGFR)突变阳性的晚期非小细胞肺癌(NSCLC)患者,其一线治疗药物众多且疗效显著,彻底改变了晚期NSCLC治疗格局。然而,不同的EGFR基因突变位点对于不同的酪氨酸激酶抑制剂(TKI)的敏感性有差异,除EGFR经典突变之外,其罕见突变类型发生率较低,对TKI的敏感性较差。因此,对于EGFR罕见突变的晚期NSCLC患者一直是临床治疗难题。本文总结1例阿美替尼治疗EGFR S768I/G719C罕见基因复合突变肺腺癌患者的疗效及安全性,为临床提供参考。
With the advancement of gene proteomics and molecular bioassay technology,the treatment of advanced lung cancer has gone through a transformation from traditional chemoradiotherapy to precise targeted therapy.Patients with advanced non-small cell lung cancer(NSCLC)with positive epidermal growth factor receptor(EGFR)mutations are now accessible to numerous first-line therapeutic agents with significant efficacy,which has transformed the treatment pattern of advanced NSCLC.However,the sensitivity of different EGFR gene mutation loci to different tyrosine kinase inhibitors(TKI)varies.With the exception of classical EGFR mutations,rare EGFR mutation types are of low incidence and show poor sensitivity to TKI.Therefore,the treatment of patients with advanced NSCLC with rare EGFR mutations has been a clinical challenge.This paper herein summarizes the efficacy and safety of almonertinib applied in a patient with lung adenocarcinoma with rare EGFR S768I/G719C gene mutations,with the purpose of providing a clinical reference.
作者
罗详冲
丁伟星
王周清
LUO Xiangchong;DING Weixing;WANG Zhouqing(Department of Cardiothoracic Surgery,Qujing Second People’s Hospital of Yunnan Province,Yunnan,Qujing 655000,China;Department of Anesthesiology,Qujing Second People’s Hospital of Yunnan Province,Yunnan,Qujing 655000,China)
出处
《中国医药科学》
2022年第20期197-200,共4页
China Medicine And Pharmacy
